http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Crime Prevention Through Environmental Design (CPTED) and Related Approaches in the United States
Matthew Robinson 한국셉테드학회 2010 한국셉테드학회지 Vol.1 No.1
In this paper, I introduce the concept of Crime Prevention Through Environmental Design (CPTED) as well as related approaches that help us to understand and prevent crime. I briefly show how this concept originated, how it is part of the broader field of environmental criminology, and the theories that underlie it. Finally, I show how it has been put into practice in the United States. The goal of the paper is to provide a solid understanding of one of the major crime prevention approaches in the United States-CPTED-as well as related approaches that are used here and elsewhere.
DETECTION OF QTL ASSOCIATED WITH RESISTANCE TO Aeromonas hydrophila IN ROHU CARP (Labeo rohita)
Nicholas Robinson,Matthew Baranski,Kanta Das Mahapatra,Jatindra Nath Saha,Sweta Das,Jashobanta Mishra,Paramananda Das,Matthew Kent,Mariann Arnyasi,Pramoda Kumar Sahoo 한국수산과학회 양식분과 2015 한국수산과학회 양식분과 학술대회 Vol.2015 No.5
Bioremediation Options for Nuclear Sites a Review of an Emerging Technology
Callum Robinson,Matthew White-Pettigrew,Samuel Shaw,Katherine Morris,James Graham,Jonathan R. Lloyd 한국방사성폐기물학회 2022 방사성폐기물학회지 Vol.20 No.3
60+ Years of nuclear power generation has led to a significant legacy of radioactively contaminated land at a number of nuclear licenced “mega sites” around the world. The safe management and remediation of these sites is key to ensuring there environmental stewardship in the long term. Bioremediation utilizes a variety of microbially mediated processes such as, enzymatically driven metal reduction or biominerialisation, to sequester radioactive contaminants from the subsurface limiting their migration through the geosphere. Additionally, some of these process can provide environmentally stable sinks for radioactive contaminants, through formation of highly insoluble mineral phases such as calcium phosphates and carbonates, which can incorporate a range of radionuclides into their structure. Bioremediation options have been considered and deployed in preference to conventional remediation techniques at a number of nuclear “mega” sites. Here, we review the applications of bioremediation technologies at three key nuclear licenced sites; Rifle and Hanford, USA and Sellafield, UK, in the remediation of radioactively contaminated land.
Kiyota, Naomi,Robinson, Bruce,Shah, Manisha,Hoff, Ana O.,Taylor, Matthew H.,Li, Di,Dutcus, Corina E.,Lee, Eun Kyung,Kim, Sung-Bae,Tahara, Makoto Mary Ann Liebert, Inc. 2017 Thyroid Vol.27 No.9
<P><B><I>Background:</I></B> While there is a clear consensus for defining radioiodine-refractory differentiated thyroid cancer (RR-DTC), it is unknown whether these criteria are equally valid for determining when radioiodine (RAI) therapy is no longer beneficial and systemic treatment should be considered. Lenvatinib, a multikinase inhibitor, significantly prolonged progression-free survival (PFS) compared to placebo in a Phase 3 trial in RR-DTC (SELECT; hazard ratio [HR]: 0.21 [99% confidence interval (CI) 0.14–0.31]; <I>p</I> < 0.001). This sub-analysis compared clinical outcomes of lenvatinib-treated patients in SELECT stratified by RR-DTC inclusion criteria.</P><P><B><I>Methods:</I></B> In SELECT, patients with measurable RR-DTC and radiologic evidence of disease progression ≤13 months prior to study entry were randomized 2:1 to lenvatinib (24 mg/day; 28-day cycle) or placebo. In this analysis, patients were stratified based on the following RR-DTC inclusion criteria: no RAI uptake, disease progression within 12 months of RAI therapy despite RAI avidity at the time of treatment, and extensive (>600 mCi) cumulative RAI exposure. All had disease progression as an inclusion criterion for SELECT.</P><P><B><I>Results:</I></B> Of 392 patients (261 lenvatinib; 131 placebo) enrolled, 275, 235, and 73 patients met the inclusion criteria for no RAI uptake, disease progression despite RAI avidity, and extensive RAI exposure, respectively. There was significant overlap between the patient groups, with 167 (42.6%) patients meeting more than one inclusion criterion. Lenvatinib improved median PFS compared to placebo in all groups (“no RAI uptake”: lenvatinib not quantifiable [NQ; CI 14.8–NQ] vs. placebo, 3.7 months [CI 2.5–5.3]; “disease progression despite RAI avidity”: lenvatinib 16.5 months [CI 12.8–NQ] vs. placebo, 3.7 months [CI 1.9–5.4]; “extensive RAI exposure”: lenvatinib 18.7 months [CI 10.7–NQ] vs. placebo, 3.6 months [CI 1.9–5.5]). Objective response rates were 71.8%, 60.0%, and 56.0% for patients with no RAI uptake, disease progression despite RAI avidity, and extensive RAI exposure, respectively. Lenvatinib-related adverse events were similar across groups.</P><P><B><I>Conclusions:</I></B> Comparable efficacy and safety profiles were observed in lenvatinib-treated patients regardless of RR-DTC criteria, possibly because of a large overlap among patients fulfilling each criterion. However, differing definitions for RR-DTC may be equally valid because both lenvatinib and placebo arms exhibited similar PFS outcomes across groups.</P>
ShadowCam Instrument and Investigation Overview
Mark Southwick Robinson,Scott Michael Brylow,Michael Alan Caplinger,Lynn Marie Carter,Matthew John Clark,Brett Wilcox Denevi,Nicholas Michael Estes,David Carl Humm,Prasun Mahanti,Douglas Arden Peckham 한국우주과학회 2023 Journal of Astronomy and Space Sciences Vol.40 No.4
ShadowCam is a National Aeronautics and Space Administration Advanced Exploration Systems funded instrument hosted onboard the Korea Aerospace Research Institute (KARI) Korea Pathfinder Lunar Orbiter (KPLO) satellite. By collecting high-resolution images of permanently shadowed regions (PSRs), ShadowCam will provide critical information about the distribution and accessibility of water ice and other volatiles at spatial scales (1.7 m/pixel) required to mitigate risks and maximize the results of future exploration activities. The PSRs never see direct sunlight and are illuminated only by light reflected from nearby topographic highs. Since secondary illumination is very dim, ShadowCam was designed to be over 200 times more sensitive than previous imagers like the Lunar Reconnaissance Orbiter Camera Narrow Angle Camera (LROC NAC). ShadowCam images thus allow for unprecedented views into the shadows, but saturate while imaging sunlit terrain.